M. Carmen Mir, MD, PhD

home / authors / m-carmen-mir-md-phd

Articles

A panel of 4 experts on bladder cancer seated at a long table

Key Takeaways on Evolving Bladder Cancer Treatment Landscape

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 21st 2023

The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Approach to Collaborative Care in Bladder Cancer

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 21st 2023

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 15th 2023

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 15th 2023

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Bladder Cancer: Treatment Options and Managing Adverse Effects

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 7th 2023

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Monitoring Patients With NMIBC

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 7th 2023

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
November 30th 2023

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
November 30th 2023

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

Read More

Latest Updated Articles

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer